Mitsuo Shimada

Active 1989–2025

183
Papers
18,453
Citations
85
h-index
172
i10-index

Citations

Citations per year for Mitsuo Shimada1939: 1 citations1994: 4 citations1995: 4 citations1996: 4 citations1997: 3 citations1998: 17 citations1999: 19 citations2000: 34 citations2001: 35 citations2002: 58 citations2003: 84 citations2004: 84 citations2005: 96 citations2006: 119 citations2007: 114 citations2008: 110 citations2009: 125 citations2010: 117 citations2011: 128 citations2012: 96 citations2013: 111 citations2014: 91 citations2015: 115 citations2016: 115 citations2017: 115 citations2018: 75 citations2019: 405 citations2020: 539 citations2021: 488 citations2022: 455 citations2023: 372 citations2024: 636 citations2025: 254 citations2026: 9 citations1940–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorJapan: 1,204 citing papers, 18% of this breakdownChina: 1,110 citing papers, 16.6% of this breakdownUnited States: 1,073 citing papers, 16.1% of this breakdownItaly: 347 citing papers, 5.2% of this breakdownGermany: 271 citing papers, 4% of this breakdownUnited Kingdom: 266 citing papers, 4% of this breakdownSouth Korea: 246 citing papers, 3.7% of this breakdownFrance: 221 citing papers, 3.3% of this breakdownSpain: 141 citing papers, 2.1% of this breakdownCanada: 131 citing papers, 2% of this breakdownSwitzerland: 112 citing papers, 1.7% of this breakdownNetherlands: 111 citing papers, 1.7% of this breakdown
0%18%Other 21.6%

Fields

  • Medicine74.2%
  • Biochemistry, Genetics and Molecular Biology14.8%
  • Immunology and Microbiology5.1%
  • Engineering2.2%
  • Computer Science1.2%
  • Neuroscience0.9%
  • Other1.6%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis9.9%
  • Cholangiocarcinoma and Gallbladder Cancer Studies6.6%
  • Organ Transplantation Techniques and Outcomes3.9%
  • Liver Disease Diagnosis and Treatment3.5%
  • Pancreatic and Hepatic Oncology Research3.5%
  • Gallbladder and Bile Duct Disorders3.4%
  • Other69.2%

Coauthors

All papers

Open in search
  1. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Liver Cancer 2021 cited by 665

  2. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Hepatology Research 2023 cited by 269

  3. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway

    Authors: , , , , , , , - International Journal of Oncology 2021 cited by 170

  4. Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction

    Authors: , , , , , , - Cell Communication and Signaling 2018 cited by 188

  5. Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial)

    Authors: , , , , , , , , , , , , , , , , , - Liver Cancer 2021 cited by 198

  6. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takehito Otsubo, Shin Ishihara, Takeshi Takahara, Mitsuo Shimada, Michiaki Unno, M Imamura, Nobuhiro Ohkochi, Yoshiaki Murakami, Jiro Fujimoto, Shinichi Ikuta, Y Fujino, Minoru Uebayashi, Shuichi Ishiyama, Norihisa Takakura, Yusuke Kumamoto, Takehito Kato, Isaku Yoshioka, Shinji Üemoto, Katsuhiko Yanaga - British journal of surgery 2018 cited by 395

  7. Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1

    Authors: , , , - Pharmaceuticals 2023 cited by 48

  8. Intraoperative 3D Hologram Support With Mixed Reality Techniques in Liver Surgery

    Authors: , , , , , , , - Annals of Surgery 2019 cited by 154

  9. Inhibition of the VEGF signaling pathway attenuates tumor‑associated macrophage activity in liver cancer

    Authors: , , , , , , , , , , - Oncology Reports 2022 cited by 65

  10. A Risk Model for Esophagectomy Using Data of 5354 Patients Included in a Japanese Nationwide Web-Based Database

    Authors: , , , , , , , , , , - Annals of Surgery 2014 cited by 598

  11. An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer

    Authors: , , , , , , , , , , - Molecular Cancer 2023 cited by 63

  12. Early experiences of endoscopic procedures in general surgery assisted by a computer-enhanced surgical system

    Authors: , , , , , , , , , , - Surgical Endoscopy 2002 cited by 297

  13. Cancer‐associated adipocytes promote pancreatic cancer progression through SAA1 expression

    Authors: , , , , , , , , , , , , , - Cancer Science 2020 cited by 128

  14. Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023

    Authors: , , , , , , , , , , , , , , , , , - Liver Cancer 2024 cited by 47

  15. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma

    Authors: , , , , , , , , , , - Cells 2023 cited by 35

  16. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update

    Authors: , , , , , , , , , , , , , , , , , , , , - Hepatology Research 2019 cited by 533

  17. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

    Authors: , , , , , , , , , , , - British Journal of Cancer 2009 cited by 440

  18. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer

    Authors: , , , , , , , , - British Journal of Cancer 2010 cited by 240

  19. Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis

    Authors: , , , , , , , , , , , , , , - International Journal of Oncology 2012 cited by 366

  20. Significance of Frailty in Prognosis After Hepatectomy for Elderly Patients with Hepatocellular Carcinoma

    Authors: , , , , , , , , - Annals of Surgical Oncology 2020 cited by 68

  21. TIMP1 promotes cell proliferation and invasion capability of right‐sided colon cancers via the FAK/Akt signaling pathway

    Authors: , , , , , , , , , , , - Cancer Science 2022 cited by 49

  22. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Atsushi Suetsugu, Yoichi Hiasa, Hisayoshi Watanabe, Takuya Genda, Isao Sakaida, Shuhei Nishiguchi, Koichi Takaguchi, Eiji Tanaka, Junichi Sugihara, Mitsuo Shimada, Yasuteru Kondo, Yosuke Kawai, Kaname Kojima, Masao Nagasaki, Katsushi Tokunaga, Yasuhito Tanaka - Gastroenterology 2017 cited by 138

  23. Epigallocatechin‑3‑gallate hinders metabolic coupling to suppress colorectal cancer malignancy through targeting aerobic glycolysis in cancer‑associated fibroblasts

    Authors: , , , , , , , , - International Journal of Oncology 2022 cited by 41

  24. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells

    Authors: , , , , , , , , - PLoS ONE 2021 cited by 39